Systemic Autoimmune Diseases in Patients Hospitalized with COVID-19 in Spain: A Nation-Wide Registry Study

Victor Moreno-Torres 1,4, Carmen de Mendoza 1,2, Susana Mellor-Pita 1, María Martínez-Urbistondo 1, Pedro Durán-del Campo 1, Pablo Tutor-Ureta 1, José-Manuel Vázquez-Comendador 1, Jorge Calderón-Parrá 1, Elena Múñez-Rubio 1, Antonio Ramos-Martínez 1, Ana Fernández-Cruz 1, Raquel Castejón 1 and Juan-Antonio Vargas-Nuñez 1,3

1 Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28660 Madrid, Spain; cmendoza.cdm@gmail.com (C.d.M.); susanamellor@hotmail.com (S.M.-P.); mmurbistondo@gmail.com (M.M.-U.); pedrodurandc@hotmail.com (P.D.-d.C.); pablo.tutor@hotmail.com (P.T.-U.); koldovazquez@gmail.com (J.-M.V.-C.); jorge50390@gmail.com (J.C.-P.); elmuru@gmail.com (E.M.-R.); aramos220@gmail.com (A.R.-M.); analcruz999@gmail.com (A.F.-C.); raquel.castejon@salud.madrid.org (R.C.);
juanantonio.vargas@salud.madrid.org (J.-A.V.-N.)

2 Pharmaceutical and Health Sciences, University CEU-San Pablo, 28003 Madrid, Spain

3 Medicine Department, School of Medicine, Universidad Autónoma de Madrid, 28029 Madrid, Spain

* Correspondence: victor.moreno.torres.1988@gmail.com

Abstract: We aimed to evaluate the clinical outcome of Systemic Autoimmune Diseases (SADs) patients hospitalized with COVID-19 in Spain, before the introduction of SARS-CoV-2 vaccines. A nationwide, retrospective and observational analysis of the patients admitted during 2020, based on the ICD10 codes in the National Registry of Hospital Discharges, was performed. Among 117,694 patients, only 892 (0.8%) presented any type of SAD before COVID-19-related admission: Sjogren’s Syndrome constituted 25%, Systemic Vasculitides 21%, Systemic Lupus Erythematosus 19%, Sarcoidosis 17%, Systemic Sclerosis 11%, Mixed and Undifferentiated Connective Tissue Disease 4%, Behçet’s Disease 4% and Inflammatory Myopathies 2%. The in-hospital mortality rate was higher in SAD individuals (20% vs. 16%, p < 0.001). After adjustment by baseline conditions, SADs were not associated with a higher mortality risk (OR = 0.93, 95% CI 0.78–1.11). Mortality in the SADs patients was determined by age (OR = 1.05, 95% CI 1.04–1.07), heart failure (OR = 1.67, 95% CI 1.10–2.49), chronic kidney disease (OR = 1.29, 95% CI 1.05–1.59) and liver disease (OR = 1.97, 95% CI 1.13–3.44). In conclusion, the higher COVID-19 mortality rate seen in SADs patients hospitalized in Spain in 2020 was related to the higher burden of comorbidities, secondary to direct organ damage and sequelae of their condition. Whilst further studies should evaluate the impact of baseline immunosuppression on COVID-19 outcomes in this population, efforts should be focused on the optimal management of SAD to minimize the impact of the organ damage that has been shown to determine COVID-19 prognosis.

Keywords: COVID-19; SARS-CoV-2; Systemic Autoimmune Diseases; mortality; Sjogren’s Syndrome; Systemic Vasculitides; Systemic Lupus Erythematosus; Sarcoidosis; Systemic Sclerosis; Mixed and Undifferentiated Connective Tissue Disease; Behçet’s Disease; Inflammatory Myopathies

1. Introduction

The surge of SARS-CoV-2 infections in China towards the end of 2019 changed the global context in an unprecedented way. In the two years following the onset of the pandemic, more than 18 million deaths have been confirmed globally [1]. Fortunately, the experience accumulated during these two years has allowed an understanding of the wide clinical spectrum and heterogeneity of the disease. The importance of identifying populations at risk, and the subsequent need for individualizing medical care and surveillance, have been highlighted [2].
Certain conditions, including age, hypertension, obesity, chronic kidney disease or heart failure, among others, were soon revealed as predictors of COVID-19 severity [3,4]. However, the role of immunosuppression has been more controversial [5–7]. The proven efficacy of certain immunosuppressants, such as glucocorticoids and IL-6 inhibitors (e.g., tocilizumab), especially during the hyperinflammatory phase of the disease, suggests that immunosuppression could provide protection against COVID-19 [8–10]. In parallel, other authors identified better outcomes in the immunocompromised population and proposed a possible protecting role of a weaker immune response [5]. By contrast, other cohorts have indeed confirmed that baseline immunodeficiencies are associated with worse prognosis [6,7]. Taken together, it seems that the distinct etiologies of impaired immunity and the drugs prescribed for treatment might explain these differences in COVID-19 outcomes [7,11].

Systemic Autoimmune Diseases (SADs) are comprised of a group of heterogeneous disorders in which persistent immune activation leads to a chronic inflammatory environment and direct tissue injury [12]. Consequently, attenuating this uncontrolled immune response with immunosuppressants is the cornerstone of their management. In addition, previous studies have shown that patients with SADs present an impaired effective immune response towards certain agents, including viruses [13]. Therefore, COVID-19 prognosis in this population might be determined by organ damage, immunosuppression and the underlying autoimmune disease itself.

In light of these considerations, the aim of the present study was to evaluate the clinical outcomes of SADs patients hospitalized with COVID-19 in Spain, before the introduction of SARS-CoV-2 vaccines.

2. Materials and Methods

A retrospective study with data from population-based hospital discharge diagnoses at the Minimum Basic Data Set (MBDS) of the Spanish National Registry of Hospital Discharges (SNRHD) was performed. The SNRHD is a national public registry that belongs to the Spanish Ministry of Health. It records information from all patients discharged at hospitals/clinics across the country since the nineties [14]. Prior studies have been performed using this registry for other illnesses, including infectious diseases and SADs, and have demonstrated its high value for producing estimates of current burden and time trends for different clinical conditions at a national level [15,16].

2.1. Study Population

Our study was performed using all the data from 1 January to 31 December 2020 included in the SNRHD. The criteria for diseases and procedures were defined according to the International Classification of Diseases-10th Revision, Clinical Modification (ICD-10-CM). We selected all hospital admissions assigned with the code U07.1 (COVID-19) as the main diagnosis.

Data regarding demographics and outcomes, including age, gender, ethnicity, length of admission, intensive care unit (ICU) admission or death were retrieved from the database. Baseline conditions, as well as the presence of respiratory insufficiency, were recorded from other ICD-10 codes in the data set, regardless of position, for each episode of hospital admission. In addition, the Charlson Comorbidity Index (CCI), which is a well-validated composite that predicts clinical outcomes in multiple illnesses, was calculated from the previous data [17]. Among other medical conditions, it included diabetes, heart failure, dementia, chronic kidney disease, liver disease and cancer, most of which have been associated with severe COVID-19 [3,4,6]. However, we excluded connective tissue disease from this index in order to analyze SAD as a separate variable.

Patients were labelled as presenting SADs before COVID-19 related admission if any of the following diagnoses were identified: Systemic Lupus Erythematosus (SLE), Sarcoidosis, Sjogren’s Syndrome (SjS), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathies (IIM), including Dermatomyositis, Polymyositis and other Inflammatory or
Immune Myopathies, Mixed and Undifferentiated Connective Tissue Disease (MUCCTD), Behçet’s disease (BD) and Systemic Vasculitides (SVs), such as Giant Cell Arteritis, Takayasu’s Disease, Polymyalgia Nodosa and ANCA-Associated Vasculitides. Other rheumatic diseases or chronic inflammatory arthritis, such as Rheumatoid Arthritis (RA), Polymyalgia Rheumatica (PM), Psoriatic Arthritis (PsA) or other Spondylarthritides were not considered to be SADs and, therefore, were not analyzed.

2.2. Statistical Analysis

Categorical variables were reported as frequencies and percentages while continuous variables were presented by their mean and standard deviation. The significance of baseline differences and outcomes of SADs patients and non-SADs patients were determined by the Chi-square, Fisher’s or Student’s t-test, as appropriate. Multivariate logistic regression analyses were performed to determine the factors related to in-hospital mortality and the role of SADs, considering male sex, high blood pressure, obesity, CCI and respiratory insufficiency. We analyzed the overall SAD patient population and performed stratified analyses for each individual SAD as well. Finally, the main prognostic comorbidities for SAD patients were determined. For all the analyses, a significance level of 0.05 was set. Statistical analysis was performed using SPSS v. 26.0 (IBM, Madrid, Spain) software.

3. Results

3.1. Population Characteristics

A total of 117,694 adults were hospitalized in Spain with COVID-19 during 2020. Overall, 66,685 patients were male (57%) with a mean age at admission of 66.5 years (Table 1). Only 892 patients of these 117,694 patients (0.8%) presented any SAD: 225 (25%) SjS, 185 (21%) SV, 173 (19%) SLE, 149 (17%) Sarcoidosis, 100 (11%) SSC, 39 (4%) MUCCTD, 36 (4%) BD and 21 (2%) IIM. Patients with SADs were less frequently male (29% vs. 57%, \( p < 0.001 \)) and Latin-American (6% vs. 8%, \( p = 0.004 \)) than non-SADs patients. No other differences were found considering age and other ethnic groups.

Table 1. Main demographics of the COVID-19 hospitalized patients.

|                          | Total N (%) | SADs N (%) | Non-SADs N (%) | \( p \)-Value |
|--------------------------|-------------|------------|----------------|--------------|
| COVID-19 hospitalized patients | 117,694 | 892 (0.8) | 116,802 (99.2) |              |
| Mean age (mean, SD)      | 66.5 (18)   | 67.5 (15.6) | 66.5 (18) | 0.055 |
| Male sex N (%)           | 66,685 (57) | 257 (29) | 66,428 (57) | <0.001 |
| Ethnicity                |             |            |                |              |
| Caucasian                | 85,977 (73) | 667 (75) | 85,310 (73) | 0.256 |
| Arabic                   | 2786 (2) | 25 (3) | 2761 (2) | 0.380 |
| Black                    | 1592 (1) | 13 (2) | 1579 (1) | 0.770 |
| Asian                    | 387 (0.3) | 0 | 387 (0.3) | 0.129 |
| Latin-American           | 9296 (8) | 54 (6) | 9242 (8) | 0.043 |
| Hindu                    | 156 (0.1) | 2 (0.2) | 154 (0.1) | 0.331 |
| Unknown                  | 17,500 (15) | 131 (15) | 17,369 (15) | 0.920 |

SADs: Systemic Autoimmune Diseases, SD: Standard deviation.

Table 2 gives the distribution of major baseline comorbidities for COVID-19 mortality in the study population. Several differences were found between the SADs and non-SADs groups. Certain conditions, such as heart failure (18% vs. 12%, \( p < 0.001 \)), peripheral vascular disease (8% vs. 4%, \( p < 0.001 \)), chronic lung disease (23% vs. 14%, \( p < 0.001 \)), liver disease (8% vs. 5%, \( p < 0.001 \)) and chronic kidney disease (18% vs. 11%, \( p < 0.001 \)), were significantly more frequent among SADs patients, while diabetes was more frequent in the
non-SADs group (24% vs. 21%, \( p = 0.023 \)). Accordingly, the CCI was significantly higher in SADs patients (3.9 vs. 3.5, \( p < 0.001 \)).

Table 2. Distribution of major baseline comorbidities of the COVID-19 hospitalized patients.

| Comorbidity                                | Total N (%) | SADs N (%) | Non-SADs N (%) | \( p \)-Value |
|--------------------------------------------|-------------|------------|----------------|--------------|
| High blood pressure                        | 56,701 (48) | 445 (50)   | 56,256 (48)    | 0.313        |
| Diabetes mellitus                          | 28,094 (24) | 184 (21)   | 27,910 (24)    | 0.023        |
| Uncomplicated                              | 18,595 (16) | 114 (13)   | 18,481 (16)    | 0.01         |
| End-organ damage                           | 9499 (8)    | 70 (8)     | 9429 (8)       | 0.847        |
| Obesity                                    | 13,966 (12) | 101 (11)   | 13,865 (12)    | 0.674        |
| Ischemic heart disease                     | 7858 (7)    | 56 (6)     | 7802 (7)       | 0.680        |
| Heart failure                              | 14,199 (12) | 163 (18)   | 14,036 (12)    | <0.001       |
| Peripheral vascular disease                | 5059 (4)    | 68 (8)     | 4991 (4)       | <0.001       |
| CVA or TIA                                 | 7308 (6)    | 58 (7)     | 7250 (6)       | 0.683        |
| Hemiplegia                                 | 1717 (2)    | 11 (1)     | 1706 (2)       | 0.675        |
| Dementia                                   | 10,146 (9)  | 61 (7)     | 10,085 (9)     | 0.066        |
| Chronic lung disease                       | 16,814 (14) | 206 (23)   | 16,608 (14)    | <0.001       |
| Peptic ulcer disease                       | 341 (0.3)   | 3 (0.3)    | 338 (0.3)      | 0.747        |
| Liver disease                              | 6001 (5)    | 74 (8)     | 5927 (5)       | <0.001       |
| Mild                                       | 4065 (4)    | 61 (7)     | 4867 (4)       | <0.001       |
| Moderate to severe                         | 1073 (1)    | 13 (2)     | 1060 (1)       | 0.106        |
| Chronic kidney disease                     | 13,232 (11) | 160 (18)   | 13,072 (11)    | <0.001       |
| Localized solid tumor                      | 433 (0.4)   | 3 (0.3)    | 430 (0.4)      | 1            |
| Metastatic solid tumor                     | 701 (0.6)   | 3 (0.3)    | 698 (0.6)      | 0.506        |
| Leukemia                                   | 697 (0.6)   | 4 (0.4)    | 693 (0.6)      | 0.825        |
| Lymphoma                                   | 610 (0.5)   | 3 (0.3)    | 607 (0.5)      | 0.638        |
| HIV                                        | 234 (0.2)   | 2 (0.2)    | 232 (0.2)      | 0.699        |
| CCI (mean, SD)                             | 3.5 (2.6)   | 3.9 (2.4)  | 3.5 (2.6)      | <0.001       |

SADs: Systemic Autoimmune Diseases, CVA: Cerebrovascular accident, TIA: Transient ischemic attack, HIV: human immunodeficiency virus, CCI: Charlson Co-morbidity Index.

3.2. Outcomes and Mortality Risk

The clinical outcomes of the patients hospitalized with COVID-19 in Spain are shown in Table 3. Although rates of respiratory insufficiency and ICU admission did not significantly differ among the two groups, the in-hospital mortality rate was significantly higher in SADs individuals (20% vs. 16%, \( p < 0.001 \)).

Table 3. Clinical outcomes of the COVID-19 hospitalized patients according to SAD status.

| Outcome                     | Total N (%) | SADs N (%) | Non-SADs N (%) | \( p \)-Value |
|-----------------------------|-------------|------------|----------------|--------------|
| Respiratory insufficiency   | 47,529 (40) | 381 (43)   | 47,148 (40)    | 0.160        |
| ICU admission               | 11,449 (10) | 98 (11)    | 11,351 (10)    | 0.211        |
| Admission length            | 10.6 (11.7) | 11.2 (11.6)| 10.6 (11.7)    | 0.09         |
| ICU admission length        | 15.6 (17.6) | 12.3 (10.5)| 15.6 (17.6)    | 0.008        |
| In-hospital mortality       | 18,858 (16) | 174 (20)   | 18,864 (16)    | 0.05         |

SADs: Systemic Autoimmune Diseases, ICU: Intensive Care Unit.
In order to characterize the relationship between in-hospital mortality and SADs, a multivariate analysis of the whole population hospitalized with COVID-19 was performed (Table 4). Male sex (OR = 1.27, 95% CI 1.23–1.31), high blood pressure (OR = 1.11, 95% CI 1.07–1.15), obesity (OR = 1.23, 95% CI 1.17–1.30), the CCI (OR = 1.41, 95% CI 1.40–1.42) and respiratory insufficiency (OR = 2.92, 95% CI 2.21–2.37) were all independently associated with death. By contrast, SADs did not dive a raise to a higher mortality risk patients admitted with COVID-19 (OR = 0.93, 95% CI 0.78–1.11). When individual SADs conditions were considered in the analysis, one by one (Figure 1), neither SLE (OR = 0.71, 95% CI 0.47–1.07), Sarcoidosis (OR = 1.17, 95% CI 0.73–1.89), SjS (OR = 0.81, 95% CI 0.57–1.17), SSc (OR = 1.31, 95% CI 0.78–2.16), IIM (OR = 0.96, 95% CI 0.26–3.58), MUCTD (OR = 1.20, 95% CI 0.52–2.77), BD (OR = 1.35, 95% CI 0.52–3.56) or SV (OR = 1.03, 95% CI 0.72–1.46) were independently related to death after adjustment.

Table 4. Risk factors for mortality in COVID-19 hospitalized patients.

| Risk Factor   | OR (95% CI)     | p-Value |
|---------------|-----------------|---------|
| Male sex      | 1.27 (1.23–1.31)| <0.001  |
| High blood pressure | 1.11 (1.07–1.15) | <0.001  |
| Obesity       | 1.23 (1.17–1.30)| <0.001  |
| CCI           | 1.41 (1.40–1.42)| <0.001  |
| SAD           | 0.93 (0.78–1.11)| 0.433   |
| Respiratory insufficiency | 2.92 (2.21–2.37) | <0.001  |

CCI: Charlson comorbidity index, SAD: Systemic autoimmune disease.

Figure 1. Risk factors for mortality in COVID-19 hospitalized patients for each SAD. The figure shows the COVID-19 risk factors for mortality in the Spanish population in 2020, considering the different systemic autoimmune disease. A binary logistic regression analysis was performed for each SAD. HBP: High blood pressure, CCI: Charlson Co-morbidity Index, SLE: Systemic Lupus Erythemathosus, SjS: Sjogren’s Syndrome, SSc: Systemic Sclerosis, IIM: Idiopathic Inflammatory Myopathies, MUCTD: Mixed and Undifferentiated Connective Tissue Disease, BD: Behçet’s Disease, SV: Systemic Vasculitides.

Finally, the main prognostic factors for COVID-19 in the SADs population were evaluated in a multivariate analysis (Table 5). Only age (OR = 1.05, 95% CI 1.04–1.07), heart failure (OR = 1.67, 95% CI 1.10–2.49), chronic kidney disease (OR = 1.29, 95% CI 1.05–1.59) and liver disease (OR = 1.97–1.13–3.44) were found to be conditions independently related to death from COVID-19 in SAD patients.
Table 5. Risk factors for mortality in COVID-19 hospitalized patients with SADs.

| Factor                  | OR (95% CI)       | p-Value |
|-------------------------|------------------|---------|
| Age                     | 1.05 (1.04–1.07)  | <0.001  |
| Heart failure           | 1.67 (1.10–2.49)  | 0.016   |
| Chronic kidney disease  | 1.29 (1.05–1.59)  | 0.015   |
| Liver disease           | 1.97 (1.13–3.44)  | 0.018   |

CCI: Charlson comorbidity index, SADs: Systemic Autoimmune Diseases.

4. Discussion

The impact of SADs on the outcome of patients hospitalized with COVID-19 during 2020 was evaluated from this large nation-wide registry. Our results revealed that the higher burden of comorbidities in these patients was responsible for their increased mortality rates. Therefore, none of the different SADs themselves gave rise to a higher COVID-19 mortality risk.

Several studies have assessed whether rheumatic diseases are associated with worse COVID-19 outcomes, with unclear results during the early pandemic period [18–22]. In subsequent waves, larger and multicentric cohorts confirmed that increasing age and pre-existing comorbidities were associated with higher severity and mortality in these patients. However, rheumatic disease was not an independent prognostic factor [23–29]. Finally, the OpenSAFELY study, and a more recent meta-analysis published in 2022, confirmed that, while rheumatic diseases might indeed be associated with COVID-19 death, their impact on mortality is overwhelmed by other conditions, such as obesity, respiratory disease, diabetes, severe kidney chronic disease, cancer and other immunosuppressive conditions [4,30]. In addition, these major studies raised the question of the vague definition and heterogeneity of these conditions in the different cohorts. Moreover, some of the aforementioned reports also found significant differences, in terms of disease course and outcomes, when chronic inflammatory arthritis was compared to other connective tissue diseases [20,26,28,31,32]. Therefore, it seems that certain conditions, such as RA, PM, PsA or other Spondylarthritides, which in fact represent the majority of the patients included in these registries, might not be equivalent to SLE, SjS, Sarcoïdosis, SSc or SV, among others [4,20,22–25,28,29,31,32]. This is not surprising since the pathophysiology, systemic involvement, and impact on mortality among these diseases differ significantly [33–35]. Accordingly, we only analyzed in our national registry systemic rheumatic or autoimmune diseases, excluding chronic inflammatory arthritis, in order to understand their real significance in COVID-19 outcomes.

In the present study, we identified that patients with SADs presented similar respiratory insufficiency but higher mortality during hospitalization due to COVID-19 than the overall population. These differences might be accounted for by the higher number of comorbidities known to predispose to severe COVID-19, as confirmed by the multivariate analysis and identified in other populations with inflammatory mediated diseases including RA, PM or PsA [23,24,31,32]. Thus, SADs patients in our registry were admitted with similar respiratory insufficiency and COVID-19 severity, but due to their baseline conditions, their clinical outcome was significantly worse. In addition, we confirmed in one of the largest studies exploring COVID-19 outcomes in patients with rheumatic diseases, that neither SLE, SjS, Sarcoïdosis, SSc, IIM, MUCTD BD or SV, individually, were associated with a higher mortality risk. Whilst previous reports have analyzed the impact of SLE or Sarcoïdosis with similar conclusions, we identified that some of these diseases, less studied due to their lower prevalence, do not relate to worse COVID-19 outcomes [35–37].

Our results highlight that COVID-19 prognosis in SADs patients is mainly related to prior organ damage, either due to direct tissue involvement, pharmacological toxicity or sustained inflammation, and not the underlying autoimmune disease itself. From this perspective, certain conditions, such as heart failure, liver disease and chronic kidney disease, typically related to disease damage or subsequent treatments, were more frequent in SADs patients than in the general population and were, in turn, the main determinants of
mortality in SAD patients in our study. Therefore, we believe that these findings strengthen the view that the best strategy to avoid fatal outcomes from COVID-19 in this population requires that first, in order to avoid chronic and irreversible organ damage, there is prompt and effective treatment of flares, with less toxic drugs and schemes, as a priority in these patients [16,38]. Second, vaccination policies and regimes must be individualized for individuals with SADs, taking into account that these patients must be at higher risk, even at a younger age, due to a higher rate of baseline comorbidities and prior chronic organ damage [39].

Finally, COVID-19 prognosis in the SADs population might not only be determined by baseline conditions, since immunosuppression itself may play a key role. While there is conflicting evidence regarding the impact of some treatments, to date there is solid data supporting the fact that certain drugs, mostly glucocorticoids and Rituximab, are associated with worse COVID-19 outcomes, both in the general population and in patients with SADs [8,23,24,26,27,31,40]. Unfortunately, we were not able to consider this issue, since no information regarding treatments could be retrieved from the database. However, it is not difficult to conjecture, based on previous evidence, the effect that the combination of these treatments might have over a SAD patient, with the burden of comorbidities as described in our cohort, who is exposed to SARS-CoV-2.

Our study has several limitations. Whilst the SNRHD records hospital discharge diagnoses along with demographic data, this database lacks information related to previous clinical conditions, such as treatment or disease status. Therefore, we have not been able to determine the impact of disease activity and immunosuppressive drugs on COVID-19. In parallel, we were not able to precisely define COVID-19 severity considering clinical and laboratory parameters. However, we believe that the lack of this data is compensated by the size of the study population, the nation-wide spectrum of the study population and the statistical power of the analysis. Secondly, we only analyzed the year 2020 so as to avoid selection or information bias regarding vaccination in this population. However, nowadays, the majority of the population in Spain has received the complete vaccine cycle and new variants have been discovered [41]. Therefore, further studies are needed to evaluate the impact of the vaccine in this population, as well as COVID-19 outcomes in SAD patients after vaccination.

5. Conclusions

In conclusion, the COVID-19 mortality rate in patients with SADs in Spain during 2020 was 20%, significantly higher than other hospitalized patients. It was related to the higher burden of comorbidities, probably secondary to direct organ damage and sequelae of their condition, and not due to SADs themselves. Therefore, efforts should be focused on the optimal management of SADs, minimizing the impact of organ damage that has been shown to determine COVID-19 prognosis.

Author Contributions: Conceptualization, V.M.-T., C.d.M., S.M.-P., M.M.-U., P.D.-d.C., P.T.-U., J.-M.V.-C., J.-C.-P., E.M.-R., A.R.-M., A.F.-C., R.C. and J.-A.V.-N.; methodology, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N.; software, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N.; validation, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N.; formal analysis, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N.; investigation, V.M.-T., C.d.M., S.M.-P., M.M.-U., P.D.-d.C., P.T.-U., J.-M.V.-C., J.C.-P., E.M.-R., A.R.-M., A.F.-C., R.C. and J.-A.V.-N.; resources, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N.; data curation, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N.; writing—original draft preparation, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N.; writing—review and editing, V.M.-T., C.d.M., S.M.-P., M.M.-U., P.D.-d.C., P.T.-U., J.-M.V.-C., J.C.-P., E.M.-R., A.R.-M., A.F.-C., R.C. and J.-A.V.-N.; visualization, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N.; supervision, C.d.M., M.M.-U., R.C. and J.-A.V.-N.; project administration, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N.; funding acquisition, V.M.-T., C.d.M., M.M.-U., R.C. and J.-A.V.-N. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Sociedad Española de Medicina Interna and Instituto de Salud Carlos III (Expedient Number CM19/00223).
Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of Clinical Research Ethics Committee of Puerta de Hierro University Hospital (PI_134-30, 6/25/2020).

Informed Consent Statement: The database was provided by the Spanish Ministry of Health after removal of all potential patient identifiers. In accordance with the Spanish legislation, patient’s informed consent was not needed for this analysis.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available since the database analysis has to be approved by the Spanish Ministry of Health.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020–2021. *Lancet* 2022, 39, 1513–1536. [CrossRef]
2. Moreno-Torres, V.; Muñoz-Serrano, A.; Calderón-Parras, J.; Mills-Sánchez, P.; Pintos-Pascual, I.; Rodríguez-Ollerøs, C.; Ibáñez-Estéllvez, F.; Tung-Chen, Y.; Ramos-Martínez, A.; A Vargas-Núñez, J.; et al. Mortality by COVID-19 Before Vaccination—One Year Experience of Hospitalized Patients in Madrid. *Int. J. Infect. Dis.* 2022, 116, 339–343. [CrossRef]
3. Graselli, G.; Zaninelli, A.; Zanella, A.; Antonelli, M.; Cabrini, L.; Castelli, A.; Cereda, D.; Coluccello, A.; Foti, G.; Fumagalli, R.; et al. Baseline characteristics and outcomes of 1591 patients admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020, 323, 1574–1581. [CrossRef]
4. Moreno-Torres, V.; Muñoz-Serrano, A.; Calderón-Parras, J.; Mills-Sánchez, P.; Pintos-Pascual, I.; Rodríguez-Ollerøs, C.; Ibáñez-Estéllvez, F.; Tung-Chen, Y.; Ramos-Martínez, A.; A Vargas-Núñez, J.; et al. Mortality by COVID-19 Before Vaccination—One Year Experience of Hospitalized Patients in Madrid. *Int. J. Infect. Dis.* 2022, 116, 339–343. [CrossRef]
5. Moreno-Torres, V.; Muñoz-Serrano, A.; Calderón-Parras, J.; Mills-Sánchez, P.; Pintos-Pascual, I.; Rodríguez-Ollerøs, C.; Ibáñez-Estéllvez, F.; Tung-Chen, Y.; Ramos-Martínez, A.; A Vargas-Núñez, J.; et al. Mortality by COVID-19 Before Vaccination—One Year Experience of Hospitalized Patients in Madrid. *Int. J. Infect. Dis.* 2022, 116, 339–343. [CrossRef]
6. Martínez-Uribistondo, M.; Gutiérrez-Rojas, Á.; Andrés, A.; Gutiérrez, I.; Escudero, G.; García, S.; Gutiérrez, A.; Sánchez, E.; Herráiz, J.; De La Fuente, S.; et al. Severe Lymphopenia as a Predictor of COVID-19 Mortality in Immunosuppressed Patients. *J. Clin. Med.* 2021, 10, 3595. [CrossRef] [PubMed]
7. Bellou, V.; Tzoulaki, I.; van Smeden, M.; Moons, K.G.M.; Evangelou, E.; Belbasis, L. Prognostic factors for adverse outcomes in patients with COVID-19: A field-wide systematic review and meta-analysis. *Eur. Respir. J.* 2020, 51, e61–e66. [CrossRef] [PubMed]
8. Horby, P.; Lim, W.S.; Emberson, J.R.; Matham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; et al. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19. *N. Engl. J. Med.* 2021, 384, 693–704. [CrossRef] [PubMed]
9. Stone, J.H.; Frigaut, M.J.; Serling-Boyd, N.J.; Fernandes, A.D.; Harvey, L.; Foulkes, A.S.; Horick, N.K.; Healy, B.C.; Shah, R.; Bensaci, A.M.; et al. BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with COVID-19. *JAMA* 2021, 325, 81, 339–343. [CrossRef] [PubMed]
10. Ruiz-Antor, B.; Sancho-López, A.; Moreno-Torres, V.; de Pablo-López, I.; García-López, P.; Abad-Santos, F.; Rosso-Fernández, C.M.; Aldea-Perona, A.; Montané, E.; et al. TOCICOV-study group. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study. *Infect. Dis. Ther.* 2021, 10, 347–362. [CrossRef] [PubMed]
11. Calderón-Parras, J.; Cuervas-Mons, V.; Moreno-Torres, V.; de Pablo-López, I.; García-López, P.; Abad-Santos, F.; Rosso-Fernández, C.M.; Aldea-Perona, A.; Méndez-Bailón, M.; et al. SEMI-COVID-19 Network. Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: Analysis of a nationwide registry. *Int. J. Infect. Dis.* 2022, 116, 51–58. [CrossRef] [PubMed]
12. Wahren-Herlenius, M.; Dörner, T. Immunopathogenic mechanisms of systemic autoimmune disease. *Lancet* 2013, 382, 819–831. [CrossRef]
13. Rigante, D.; Esposito, S. Infections and Systemic Lupus Erythematosus: Binding or Sparring Partners? *Int. J. Mol. Sci.* 2015, 16, 17331–17343. [CrossRef]
14. Ministerio de Sanidad. Servicios Sociales e Igualdad. Real Decreto 69/2015, de 6 febrero, por el que se regula el Registro de Actividad Sanitaria Especializada. *Boletín Del Estado* 2015, 35, 1078–1080. Available online: http://www.boe.es/eli/es/rd/2015/02/06/69/ (accessed on 15 March 2022).
15. Ramos-Rincon, J.M.; Menchi-Elanzi, M.; Pinargote-Celorio, H.; Mayoral, A.; Gonzalez-Alcaide, G.; de Mendoza, C.; Barreiro, P.; Gómez-Gallego, F.; Corral, O.; Soriano, V. Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. *AIDS* 2022, 36, 249–256. [CrossRef] [PubMed]
16. Moreno-Torres, V.; Tarín, C.; Ruiz-Irastorza, G.; Castejón, R.; Gutiérrez-Rojas, A.; Royuela, A.; Campo, P.D.-D.; Mellor-Pita, S.; Tutor, P.; Rosado, S.; et al. Trends in hospital admissions and death causes in patients with systemic lupus erythematosus: Spanish National Registry. *J. Clin. Med.* 2021, 10, 5749. [CrossRef]
17. Charlson, M.; Pompei, P.; Ales, K.; MacKenzie, C. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J. Chronic Dis.* 1987, 40, 373–383. [CrossRef]

18. Huang, Y.; Chen, Z.; Wang, Y.; Han, L.; Qin, K.; Huang, W.; Huang, Y.; Wang, H.; Shen, P.; Ba, X.; et al. Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: A retrospective study. *Ann. Rheum. Dis.* 2020, 79, 1163–1169. [CrossRef]

19. Haberman, R.; Axelrad, J.; Chen, A.; Castillo, R.; Yan, D.; Izmirl, P.; Neirnann, A.; Adhikari, S.; Hudesman, D.; Scher, J.U. COVID-19 in Immune-Mediated Inflammatory Diseases—Case Series from New York. *N. Engl. J. Med.* 2020, 383, 85–88. [CrossRef]

20. Pablos, J.L.; Galindo, M.; Carmona, L.; Lledó, A.; Retuerto, M.; Blanco, R.; Gonzalez, A.; Martinez-Lopez, D.; Castrejón, I.; RIER Investigators Group; et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study. *Ann. Rheum. Dis.* 2020, 79, 1544–1549. [CrossRef]

21. Zhong, J.; Shen, G.; Yang, H.; Huang, A.; Chen, X.; Dong, L.; Wu, B.; Su, L.; Hou, X.; Song, S.; et al. COVID-19 in patients with rheumatic disease in Hubei province, China: A multicentre retrospective observational study. *Lancet Rheumatol.* 2020, 2, e557–e564. [CrossRef]

22. Fredi, M.; Cavazana, I.; Moschetti, L.; Andreoli, L.; Franceschini, F.; Brescia Rheumatology COVID-19 Study Group. Short term outcomes of COVID-19 in patients with rheumatic diseases in northern Italy: A single-centre observational and case-control study. *Lancet Rheumatol.* 2020, 2, e549–e556. [CrossRef]

23. Gianfrancesco, M.; Hrych, K.L.; Al-Adely, S.; Carmona, L.; I Danila, M.; Gossec, L.; Izadi, Z.; Jacobsohn, L.; Katz, P.; Lawson-Tovey, S.; et al. COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann. Rheum. Dis.* 2020, 79, 859–866. [CrossRef] [PubMed]

24. Hasseli, R.; Mueller-Ladner, U.; Hoyer, B.F.; Krause, A.; Lorenz, H.-M.; Pfeil, A.; Richter, J.; Schäfer, M.; Schmeiser, T.; Strangfeld, A.; et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. *RMD Open* 2021, 7, e001464. [CrossRef] [PubMed]

25. D’Silva, K.M.; Jorge, A.; Cohen, A.; McCormick, N.; Zhang, Y.; Wallace, Z.S.; Choi, H.K. COVID-19 Outcomes in Patients with Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. *Arthritis Rheumatol.* 2021, 73, 914–920. [CrossRef]

26. Strangfeld, A.; Schäfer, M.; Gianfrancesco, M.A.; Lawson-Tovey, S.; Liew, J.W.; Ljung, L.; Mateus, E.F.; Richez, C.; Santos, M.J.; Schmajuk, G.; et al. COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann. Rheum. Dis.* 2021, 80, 930–942. [CrossRef]

27. Montero, F.; Martínez-Barrio, J.; Serrano-Benavente, B.; González, T.; Rivera, J.; Collada, J.M.; Castrejón, I.; Álvaro-Gracia, J. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: Clinical characteristics of poor outcomes. *Rheumatol. Int.* 2020, 40, 1593–1598. [CrossRef]

28. Ayala Gutiérrez, M.D.M.; Rubio-Rivas, M.; Romero Gómez, C.; Sáez, A.M.; de Pedro, I.P.; Homs, N.; García, B.A.; Carvajal, C.C.; Fernández, F.A.; Pérez, J.L.B.; et al. On Behalf of The Semi-COVID-Network. Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. *J. Clin. Med.* 2021, 10, 1844. [CrossRef]

29. Santos, C.S.; Morales, C.M.; Álvarez, E.D.; Castro, C.Á.; Robles, A.L.; Sandoval, T.P. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. *Clin. Rheumatol.* 2020, 39, 2789–2796. [CrossRef]

30. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020, 584, 430–436. [CrossRef]

31. Bachiller-Corral, J.; Boteanu, A.; García-Villanueva, M.J.; de la Puente, C.; Revenga, M.; Diaz-Miguel, M.C.; Rodríguez-García, A.; Morell-Hita, J.L.; Valero, M.; Larena, C.; et al. Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases. *J. Rheumatol.* 2021, 48, 1098–1102. [CrossRef] [PubMed]

32. Freites Núñez, D.D.; Leon, L.; Mucientes, A.; Rodriguez-Rodriguez, L.; Urgelles, J.F.; García, A.M.; I Colomer, J.; A Jover, J.; Fernandez-Gutierrez, B.; Abascal, L. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. *Ann. Rheum. Dis.* 2020, 79, 1393–1399. [CrossRef] [PubMed]

33. Bournia, V.K.; Fragoulis, G.E.; Mitrou, P.; Mathioudakis, K.; Tsolakidis, A.; Konstantonis, G.; Vourli, G.; Paraskevis, D.; Tektonidou, M.G.; Sfikakis, P.P. All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015–2019. *RMD Open* 2021, 7, e001694. [CrossRef] [PubMed]

34. Mitratza, M.; Klijn, B.; Hak, A.E.; Kardaun, J.W.P.F.; Kunst, A.E. Systemic autoimmune disease as a cause of death: Mortality burden and comorbidities. *Rheumatology* 2021, 60, 1321–1330. [CrossRef] [PubMed]

35. Hyrich, K.L.; Machado, P.M. Rheumatic disease and COVID-19: Epidemiology and outcomes. *Nat. Rev. Rheumatol.* 2021, 17, 71–72. [CrossRef]

36. Raiker, R.; Pakhchanian, H.; De Young, C.; Gupta, L.; Kardeş, S.; Ahmed, S.; Kavadiachanda, C. Short term outcomes of COVID-19 in lupus: Propensity score matched analysis from a nationwide multi-centric research network. *J. Autoimmu.n* 2021, 125, 102730. [CrossRef]
37. Brito-Zerón, P.; Gracia-Tello, B.; Robles, A.; Alguacil, A.; Bonet, M.; De-Escalante, B.; Noblejas-Mosso, A.; Gómez-De-La-Torre, R.; Akasbi, M.; Pérez-De-Lis, M.; et al. On Behalf of The SarcoGEAS-Semi Registry. Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. *Viruses* 2021, 13, 1000. [CrossRef]

38. Ruiz-Irastorza, G.; Bertsias, G. Treating systemic lupus erythematosus in the 21st century: New drugs and new perspectives on old drugs. *Rheumatology* 2020, 59, v69–v81. [CrossRef]

39. Brito-Zerón, P.; Sisó-Almirall, A.; Flores-Chavez, A.; Retamozo, S.; Ramos-Casals, M. SARS-CoV-2 infection in patients with systemic autoimmune diseases. *Clin. Exp. Rheumatol.* 2021, 39, 676–687. [CrossRef]

40. Calderón-Parra, J.; Muñez-Rubio, E.; Fernández-Cruz, A.; García-Sánchez, M.C.; Maderuelo-González, E.; López-Dosil, M.; Calvo-Salvador, M.; Baños-Pérez, I.; Valle-Falcones, M.; Ramos-Martínez, A. Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies. *Clin. Infect. Dis.* 2022, 74, 1786–1794. [CrossRef]

41. Barandalla, I.; Alvarez, C.; Barreiro, P.; de Mendoza, C.; González-Crespo, R.; Soriano, V. Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. *Int. J. Infect. Dis.* 2021, 112, 81–88. [CrossRef] [PubMed]